RuckTBittnerSWiendlHet al. Alemtuzumab in multiple sclerosis: Mechanism of action and beyond. Int J Mol Sci2015; 16: 16414–16439.
2.
WiendlHKieseierB.Multiple sclerosis: Reprogramming the immune repertoire with alemtuzumab in MS. Nat Rev Neurol2013; 9: 125–126.
3.
BakerDHerrodSSAlvarez-GonzalezCet al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of alemtuzumab. JAMA Neurol2017; 74: 961–969.
4.
HaghikiaADendrouCASchneiderRet al. Severe B-cell-mediated CNS disease secondary to alemtuzumab therapy. Lancet Neurol2017; 16: 104–106.
5.
WillisMDHope-GillBFlood-PageP. Sarcoidosis following alemtuzumab treatment for multiple sclerosis. Mult Scler 2018; 24: 1779�1782.
6.
GrafJRingelsteinMLepkaK. Acute sarcoidosis in a multiple sclerosis patient after alemtuzumab treatment. Mult Scler 2018; 24: 1776�1778.
7.
ChurchLWPChopraAJudsonMA.Paradoxical reactions and the immune reconstitution inflammatory syndrome. Microbiol Spectr2017; 5. DOI: 10.1128/microbiolspec.TNMI7-0033-2016.
8.
EichauSLopez-RuizRRuiz-PenaJLet al. Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab. Rev Neurol2018; 66: 395–396.
9.
ZimmermannJBuhlTMullerM.Alopecia universalis following alemtuzumab treatment in multiple sclerosis: A barely recognized manifestation of secondary autoimmunity-report of a case and review of the literature. Front Neurol2017; 8: 569.
10.
SaarelaMSenthilKJonesJet al. Hemophagocytic lymphohistiocytosis in 2 patients with multiple sclerosis treated with alemtuzumab. Neurology2018; 90: 849–851.
11.
RorkJFRashighiMHarrisJE.Understanding autoimmunity of vitiligo and alopecia areata. Curr Opin Pediatr2016; 28: 463–469.
12.
JonesJLPhuahCLCoxALet al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest2009; 119: 2052–2061.
13.
TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology1999; 53: 457–465.
